Related Experiment Video
Updated: Oct 11, 2025
Integration of Bioinformatics Approaches and Experimental Validations to Understand the Role of Notch Signaling in Ovarian Cancer
Published on: January 12, 2020
Integral membrane protein 2A enhances sensitivity to chemotherapy via notch signaling pathway in cervical cancer
Yan Li1, Jianhua Wang2, Chengzhen Gao1
1Department of Obstetrics and Gynecology, The Yancheng Clinical College of Xuzhou Medical University, the First People's Hospital of Yancheng, Yancheng, China.
Abstract:
As the second most common cancer among women, cervical cancer is a huge threat to their health all over the world. Integral membrane protein 2A (ITM2A), a member of the Type II Integral Membrane protein (ITM2) family, has been reported to act as a tumor suppressor in breast cancer and ovarian cancer. Moreover, the low expression of ITM2A was associated with cervical adenocarcinoma. However, the function of ITM2A in drug resistance in cervical cancer remains unclear. Here, we used bioinformatics methods to screen differentially expressed genes (DEGs) closely related to chemotherapeutic relapse cervical carcinoma. ITM2A is downregulated in cervical tumor tissues and is associated with poor survival. Furthermore, ITM2A is also downregulated in cervical cancer cells with cisplatin resistance. Overexpression of ITM2A increases the cisplatin sensitivity of cervical cancer cells. Mechanically, ITM2A upregulation mediates the sensitivity of cervical cancer cell through Notch signaling pathway. Our study suggests that ITM2A may serve as a target in mediating cisplatin-resistant cervical cancer.
Insights
Integral membrane protein 2A (ITM2A) is downregulated in cervical cancer, reducing cisplatin sensitivity. Restoring ITM2A levels may overcome drug resistance by influencing the Notch signaling pathway.
Area of Science:
- Oncology
- Molecular Biology
- Biochemistry
Background:
- Cervical cancer is a major global health concern for women.
- Integral membrane protein 2A (ITM2A) acts as a tumor suppressor in other cancers.
- ITM2A's role in cervical cancer drug resistance was previously unknown.
Purpose of the Study:
- To investigate the function of ITM2A in chemoresistant cervical cancer.
- To identify potential therapeutic targets for overcoming cisplatin resistance.
Main Methods:
- Bioinformatics analysis to screen differentially expressed genes (DEGs).
- Analysis of ITM2A expression in cervical tumor tissues and cell lines.
- Assessment of ITM2A's effect on cisplatin sensitivity in cancer cells.
- Investigation of the Notch signaling pathway's involvement.
Main Results:
- ITM2A is downregulated in cervical tumor tissues and associated with poor survival.
- ITM2A is also downregulated in cisplatin-resistant cervical cancer cells.
- Overexpression of ITM2A enhances cisplatin sensitivity.
- ITM2A upregulation mediates sensitivity via the Notch signaling pathway.
Conclusions:
- ITM2A downregulation contributes to cisplatin resistance in cervical cancer.
- ITM2A may serve as a predictive biomarker for treatment response.
- Targeting ITM2A could be a novel strategy for treating chemoresistant cervical cancer.
Related Concept Videos
03:14Notch Signaling Pathway
The Notch gene came into the limelight in 1914 after the discovery that its mutation in Drosophila melanogaster leads to a serrated (or "notched") wing margin phenotype. It was not...
01:12Role Of Notch Signalling In Intestinal Stem Cell Renewal
Direct cell-to-cell contact is needed for the activation of Notch signaling. The signal is initiated when a notch ligand binds to a receptor on an adjacent cell, also...
02:38Mitogens and the Cell Cycle
01:31The Intrinsic Apoptotic Pathway
01:15Receptor Downregulation in MVBs
The EGFR can initiate signaling pathways that lead to cell proliferation, migration, and differentiation. Overexpression of EGFR stimulates cells to proliferate. Excessive EGFR...
01:28Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists